Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $262.9K | $221.6K | $32.7K | $114.8K | $122.7K | $12.5K | $0 | $0 |
| Cost of revenue | $146.6K | $0 | $0 | $0 | $205.8K | $1.8K | $1.0M | $1.0M |
| Gross profit | $116.3K | $221.6K | $32.7K | $114.8K | −$83.1K | −$1.8M | −$1.0M | −$1.0M |
| Gross margin | 44.3% | 100.0% | 100.0% | 100.0% | -67.8% | -14245.2% | — | — |
| R&D | $416.2K | $719.9K | $791.1K | $474.0K | $472.6K | $1.8M | $1.2M | $417.4K |
| Operating income | −$722.9K | −$1.1M | −$1.3M | −$836.8K | −$774.8K | −$2.9M | −$2.9M | −$2.0M |
| EBITDA | −$694.7K | −$1.0M | −$1.3M | −$795.7K | −$734.1K | −$2.5M | −$1.8M | −$913.5K |
| Net income | −$286.0K | −$1.2M | −$539.6K | −$1.1M | −$793.1K | −$1.7M | −$2.8M | −$1.9M |
| Net margin | -108.8% | -519.9% | -1650.7% | -956.9% | -646.5% | -13695.1% | — | — |
| EPS (diluted) | -0.06 | -0.20 | -0.09 | -0.19 | -0.13 | -0.34 | -0.52 | -0.35 |
Annual figures · source: Financial Modeling Prep
EVOLUTIONARY GENOMICS INC
No one on the platform currently holds FNAM.
No tracked institution reports a position in FNAM as of their last filing.
| Execution date | Ratio |
|---|---|
| 2015-10-19 | 1-for-60.8826484reverse |
No one on the platform has traded FNAM yet.
| $11M |
| — |
| LIFDLFTD Partners Inc. | $0.16 | +0.00% | $2M | — |
| REPCFRepliCel Life Sciences Inc. | $0.00 | +0.00% | $7000 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.